Skip to content

Stimulation of brain with magnetic pulses for the treatment of negative symptoms in schizophrenia.

Optimized Prefrontal and Cerebellar Intermittent Theta Burst Stimulation for Negative Symptoms of Schizophrenia (OPCINSS): A Double-Blind Randomized Placebo- Controlled Trial with Imaging and Electrophysiological Outcomes - OPCINSS

Status
Recruiting
Phases
Phase 2Phase 3
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2022/07/044077
Enrollment
171
Registered
2022-07-18
Start date
Unknown
Completion date
Unknown
Last updated
2023-05-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: F20- Schizophrenia

Interventions

Intervention1: Prefrontal intermittent Theta Burst Stimulation (iTBS): Real iTBS is delivered to left dorsolateral prefrontal cortex (DLPFC) and sham iTBS to cerebellar vermis area 7B. 1800 pulses of

Sponsors

National Institute of Mental Health and Neurosciences NIMHANS
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. Patients diagnosed with schizophrenia as per Diagnostic and Statistical Manual â?? 5 (DSM-5) (American Psychiatric Association, 2013) criteria, aged 18-60 years of either sex will be recruited from the outpatient and inpatient settings of the National Institute of Mental Health and Neurosciences (NIMHANS), Bengaluru, India. 2. At least one of the domains of negative symptoms should be at least of a moderate severity as indicated by Scale for Assessment of Negative Symptoms (SANS) global score of 3 or more on affective flattening OR alogia OR avolition-apathy OR anhedonia-asociality (Andreasen et al., 2005) 3. Stable dose of oral antipsychotics (defined as <25% change in dose) for the past 6 weeks and/or parenteral antipsychotics for the past 12 weeks

Exclusion criteria

Exclusion criteria: 1. Significant neurological or medical disorders that may produce cognitive impairment 2. Substance abuse or dependence (except nicotine) within the past 3 months 3. Persistent suicidal or homicidal behavior 4. Pregnant, lactating or in the postpartum state 5. Self-reported visual or auditory impairment that may interfere with study evaluations 6. Risk factors for TMS procedures and/or MRI as assessed by standard questionnaires (Ghadimi & Sapra, 2020; Rossi et al., 2011)

Design outcomes

Primary

MeasureTime frame
Scale for the Assessment of Negative symptoms (SANS)Timepoint: Baseline, Week-3 (after 18 days of intervention), Week-12 (after 3 months of intervention)

Secondary

MeasureTime frame
Glu and GABA/Glu in Left DLPFC, right DLPFC and Anterior Cingulate Cortex (ACC) through magnetic resonance spectroscopy (MRS). In 45 subjects (15 in each arm) only.Timepoint: Baseline, Week-3 (after 18 days of intervention);Resting State Functional Connectivity (RSFC) between the target areas (vermis and left DPLFC) and different subdivisions of the prefrontal cortex.Timepoint: Baseline, Week-3 (after 18 days of intervention);Spectral power of TMS-evoked gamma band oscillations in the prefrontal cortex elicited through TMS-EEGTimepoint: Baseline, Week-3 (after 18 days of intervention);White matter integrity in the form of Fractional Anisotropy (FA) of the superior cerebellar peduncle, frontal lobar white matter, and corpus callosumTimepoint: Baseline, Week-3 (after 18 days of intervention)

Countries

India

Contacts

Public ContactRakshathi Basavaraju

National Institute of Mental Health and Neurosciences (NIMHANS)

rakshathi.b@gmail.com08026995320

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026